Tran Quang Duc, Nguyen Thi Nu, Nguyen Di Khanh, Dao Huy Cu, Vu Thi Quynh Chi, Tran Thi Khuyen, Nguyen Thi Hoa Huyen
{"title":"美国成年人维生素 C 缺乏症的患病率及其与中风风险的关系:一项跨越 15 年、超过 13,000 人参与的横断面分析。","authors":"Tran Quang Duc, Nguyen Thi Nu, Nguyen Di Khanh, Dao Huy Cu, Vu Thi Quynh Chi, Tran Thi Khuyen, Nguyen Thi Hoa Huyen","doi":"10.1177/02601060241281882","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Stroke presents a significant global health challenge. Despite its potential for cardiovascular protection, the role of vitamin C (VTMC) in stroke risk remains contentious. <b>Aim:</b> This study aimed to assess VTMC deficiency in stroke patients and its association with stroke risk. <b>Methods:</b> We analyzed data from 13,339 adults aged 20 and above in the National Health and Nutrition Examination Survey (NHANES) between 2003 and 2018, excluding those with missing serum VTMC and stroke status. We assessed the VTMC deficiency (<11.4 µmol/L) and stroke incidence association using multivariate weighted logistic regression, adjusting for demographics, BMI, medical history, smoking, and dietary VTMC intake. <b>Results:</b> Stroke rates in the NHANES cycles 2003-2006 and 2017-2018 were 2.8% (95% CI [2.3-3.4]) and 3.3% (95% CI [2.7-4.2]), respectively. VTMC deficiency was more common in individuals with a history of stroke, with rates of 3.6% (95% CI [2.2-5.8]) and 5.3% (95% CI [3-9.1]) compared to 2.7% (95% CI [2.3-3.3]) and 3.2% (95% CI [2.5-4.1]) in the nonstroke population. Nevertheless, VTMC deficiency was distinctly prevalent across diverse demographic and health-related subgroups. Multivariate analyses invalidated any statistically significant association between VTMC deficiency and stroke risk across all employed analytical models within both time intervals. <b>Conclusions:</b> Our study does not support a link between VTMC deficiency and increased stroke risk in U.S. adults. Substantial uncertainties persist regarding the use of VTMC for stroke-related oxidative stress, dosage, and delivery methods, requiring further clinical trials. Healthcare providers should carefully consider its prevalence in specific subgroups.</p>","PeriodicalId":19352,"journal":{"name":"Nutrition and health","volume":" ","pages":"2601060241281882"},"PeriodicalIF":1.9000,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prevalence of vitamin C deficiency and its association with stroke risk among U.S. adult population: A cross-sectional analysis spanning 15 years with over 13,000 participants.\",\"authors\":\"Tran Quang Duc, Nguyen Thi Nu, Nguyen Di Khanh, Dao Huy Cu, Vu Thi Quynh Chi, Tran Thi Khuyen, Nguyen Thi Hoa Huyen\",\"doi\":\"10.1177/02601060241281882\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Background:</b> Stroke presents a significant global health challenge. Despite its potential for cardiovascular protection, the role of vitamin C (VTMC) in stroke risk remains contentious. <b>Aim:</b> This study aimed to assess VTMC deficiency in stroke patients and its association with stroke risk. <b>Methods:</b> We analyzed data from 13,339 adults aged 20 and above in the National Health and Nutrition Examination Survey (NHANES) between 2003 and 2018, excluding those with missing serum VTMC and stroke status. We assessed the VTMC deficiency (<11.4 µmol/L) and stroke incidence association using multivariate weighted logistic regression, adjusting for demographics, BMI, medical history, smoking, and dietary VTMC intake. <b>Results:</b> Stroke rates in the NHANES cycles 2003-2006 and 2017-2018 were 2.8% (95% CI [2.3-3.4]) and 3.3% (95% CI [2.7-4.2]), respectively. VTMC deficiency was more common in individuals with a history of stroke, with rates of 3.6% (95% CI [2.2-5.8]) and 5.3% (95% CI [3-9.1]) compared to 2.7% (95% CI [2.3-3.3]) and 3.2% (95% CI [2.5-4.1]) in the nonstroke population. Nevertheless, VTMC deficiency was distinctly prevalent across diverse demographic and health-related subgroups. Multivariate analyses invalidated any statistically significant association between VTMC deficiency and stroke risk across all employed analytical models within both time intervals. <b>Conclusions:</b> Our study does not support a link between VTMC deficiency and increased stroke risk in U.S. adults. Substantial uncertainties persist regarding the use of VTMC for stroke-related oxidative stress, dosage, and delivery methods, requiring further clinical trials. Healthcare providers should carefully consider its prevalence in specific subgroups.</p>\",\"PeriodicalId\":19352,\"journal\":{\"name\":\"Nutrition and health\",\"volume\":\" \",\"pages\":\"2601060241281882\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-09-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nutrition and health\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/02601060241281882\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition and health","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/02601060241281882","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
引用次数: 0
摘要
背景:中风是一项重大的全球性健康挑战。尽管维生素 C(VTMC)具有保护心血管的潜力,但其在中风风险中的作用仍存在争议。目的:本研究旨在评估中风患者的维生素 C 缺乏情况及其与中风风险的关系。方法:我们分析了 13,333 名中风患者的数据:我们分析了 2003 年至 2018 年间全国健康与营养调查(NHANES)中 13339 名 20 岁及以上成年人的数据,排除了血清 VTMC 和卒中状态缺失者。我们评估了 VTMC 的缺乏情况(结果:2003-2006 年和 2017-2018 年 NHANES 周期的中风率分别为 2.8%(95% CI [2.3-3.4])和 3.3%(95% CI [2.7-4.2])。VTMC 缺乏症在有中风史的人群中更为常见,发病率分别为 3.6%(95% CI [2.2-5.8])和 5.3%(95% CI [3-9.1]),而非中风人群的发病率分别为 2.7%(95% CI [2.3-3.3])和 3.2%(95% CI [2.5-4.1])。尽管如此,VTMC 缺乏症在不同的人口统计学和健康相关亚群中仍明显普遍存在。多变量分析结果表明,在两个时间区间内的所有分析模型中,VTMC 缺乏症与中风风险之间均无统计学意义上的显著关联。结论:我们的研究并不支持 VTMC 缺乏与美国成年人中风风险增加之间存在联系。在使用 VTMC 治疗中风相关氧化应激、剂量和给药方法方面仍存在很大的不确定性,需要进一步的临床试验。医疗服务提供者应仔细考虑其在特定亚组中的流行情况。
Prevalence of vitamin C deficiency and its association with stroke risk among U.S. adult population: A cross-sectional analysis spanning 15 years with over 13,000 participants.
Background: Stroke presents a significant global health challenge. Despite its potential for cardiovascular protection, the role of vitamin C (VTMC) in stroke risk remains contentious. Aim: This study aimed to assess VTMC deficiency in stroke patients and its association with stroke risk. Methods: We analyzed data from 13,339 adults aged 20 and above in the National Health and Nutrition Examination Survey (NHANES) between 2003 and 2018, excluding those with missing serum VTMC and stroke status. We assessed the VTMC deficiency (<11.4 µmol/L) and stroke incidence association using multivariate weighted logistic regression, adjusting for demographics, BMI, medical history, smoking, and dietary VTMC intake. Results: Stroke rates in the NHANES cycles 2003-2006 and 2017-2018 were 2.8% (95% CI [2.3-3.4]) and 3.3% (95% CI [2.7-4.2]), respectively. VTMC deficiency was more common in individuals with a history of stroke, with rates of 3.6% (95% CI [2.2-5.8]) and 5.3% (95% CI [3-9.1]) compared to 2.7% (95% CI [2.3-3.3]) and 3.2% (95% CI [2.5-4.1]) in the nonstroke population. Nevertheless, VTMC deficiency was distinctly prevalent across diverse demographic and health-related subgroups. Multivariate analyses invalidated any statistically significant association between VTMC deficiency and stroke risk across all employed analytical models within both time intervals. Conclusions: Our study does not support a link between VTMC deficiency and increased stroke risk in U.S. adults. Substantial uncertainties persist regarding the use of VTMC for stroke-related oxidative stress, dosage, and delivery methods, requiring further clinical trials. Healthcare providers should carefully consider its prevalence in specific subgroups.